| Id |
Subject |
Object |
Predicate |
Lexical cue |
| T18 |
0-196 |
Sentence |
denotes |
In this review, we discuss the pathophysiologic rationale and current evidence for the use of full-dose heparin (i.e., therapeutic rather than prophylactic dosing) as an anticoagulant in COVID-19. |
| T19 |
197-318 |
Sentence |
denotes |
We also discuss a subset of non-anticoagulant effects of heparin that may prove beneficial for the treatment of COVID-19. |
| T20 |
319-531 |
Sentence |
denotes |
Finally, we discuss potential risks associated with the implementation of heparin for the treatment of SARS-CoV-2, including but not limited to bleeding and immune-mediated heparin-induced thrombocytopenia (HIT). |
